MicroRNA-29a-5p attenuates hemorrhagic transformation and improves outcomes after mechanical reperfusion for acute ischemic stroke
Chang-Luo Li, Jin-Kun Zhuang, Zhong Liu, Zhong-Run Huang, Chun XiangiD, Qian-Yu Chen, Zexin CheniD, Zhong‐Song ShiiD
Abstract
BackgroundHemorrhage transformation (HT) following endovascular reperfusion treatment is associated with worse clinical outcomes in acute ischemic stroke patients. MicroRNA (miR) modulates several aspects of cerebral ischemia-reperfusion injury, including blood-brain barrier (BBB) integrity, inflammation, oxidative stress, and apoptosis, significantly impacting cerebral recovery and function. This study investigated the role of astrocytic miR-29a-5p in HT in the transient middle cerebral artery occlusion (MCAO) model and oxygen-glucose deprivation reoxygenation (OGD/R) model of astrocytes. MethodsMiR-29a-5p expression in the OGD/R astrocyte model was assessed. The astrocyte injury, the expression of A1 and A2 phenotypes of reactive astrocytes, and the regulation of miR-29a-5p target genes were evaluated after the miR-29a-5p intervention. A mechanical reperfusion-induced HT model was established in hyperglycemic rats using 5-hour MCAO following reperfusion at 6 hours. MiR-29a-5p agomir was administered intravenously before reperfusion. Infarct volume, HT, BBB damage, neurological score, the expression of miR-29a-5p, and its target genes were evaluated. ResultsMiR-29a-5p expression decreased in OGD/R-treated astrocytes and the peri-infarction tissue and blood of the MCAO model. Elevating miR-29a-5p levels reduced astrocyte injury, suppressed neurotoxic A1 astrocyte markers (C3, Fkbp5, and Serping1), while enhanced neuroprotective A2 astrocyte markers (S100a10 and Emp1) in the OGD/R and MCAO models. Intravenous administration of miR-29a-5p agomir increased the expression of miR-29a-5p and reduced infarct volume, reperfusion-induced HT, and BBB breakdown after ischemia, improving neurological outcomes in the MCAO model. Overexpression of miR-29a-5p effectively suppressed the expression of its direct target genes, glycogen synthase kinase 3 beta and aquaporin 4 in the OGD/R and MCAO models. ConclusionsMiR-29a-5p alleviates astrocyte injury and regulates A1 and A2 astrocyte markers, glycogen synthase kinase 3 beta, and aquaporin 4 in astrocytes subjected to ischemia-reperfusion injury. Astrocytic miR-29a-5p may be a protective target for reducing HT and improving outcomes following mechanical reperfusion in acute ischemic stroke.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 5
- FWCI
- 2.26
- Field percentile
- top 12%
- Organism
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- MicroRNA-383-5p alleviates hemorrhagic transformation and improves outcomes after endovascular recanalization for acute ischemic stroke
Qiu-Yi Jiang, Wang Qin, … Zhong‐Song Shi·bioRxiv·Dec 27, 2025
- MicroRNAs and mRNA Regulatory Network of Parenchymal Hematoma after Endovascular Mechanical Reperfusion for Acute Ischemic Stroke in Rat
Jin-Kun Zhuang, Zhong-Run Huang, … Zhong‐Song Shi·BiomedicinesPeer-reviewed·Feb 12, 2025
- The myeloid cell-driven transdifferentiation of endothelial cells into pericytes promotes the restoration of BBB function and brain self-repair after stroke
Tingbo Li, Ling Yang, … Jie-Min Jia·eLifePeer-reviewed·Jul 16, 2025
- LOX-1 and MMP-9 inhibition attenuates the detrimental effects of delayed rt-PA therapy and improves outcomes after acute ischemic stroke
Kajsa Arkelius, Trevor S. Wendt, … Saema Ansar·Circulation ResearchPeer-reviewed·Mar 19, 2024
- Decreased Astrocytic CCL5 by MiR-324-5p Ameliorates Ischemic Stroke Injury via the CCR5/ERK/CREB Pathway
Jing‐Xiu Li, Keyuan Gao, … Chenxi Sun·bioRxiv·Sep 3, 2024
- Loss of white matter tracts and persistent microglial activation in the chronic phase of ischemic stroke in female rats and the effect of miR-20a-3p treatment
Dayalan Sampath, Macy E. Zardeneta, … Farida Sohrabji·bioRxiv·Feb 1, 2025